New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
RAS is the most frequently mutated gene across human cancers, but developing inhibitors of mutant RAS has proven to be challenging. Given the difficulties of targeting RAS directly, drugs that impact the other components of pathways where mutant RAS operates may potentially be effective. However, the system-level features, including different localizations of RAS isoforms, competition between downstream effectors, and interlocking feedback and feed-forward loops, must be understood to fully grasp the opportunities and limitations of inhibiting specific targets. Mathematical modeling can help us discern the system-level impacts of these features in normal and cancer cells. New technologies enable the acquisition of experimental data that will facilitate development of realistic models of oncogenic RAS behavior. In light of the wealth of empirical data accumulated over decades of study and the advancement of experimental methods for gathering new data, modelers now have the opportunity to advance progress toward realization of targeted treatment for mutant RAS-driven cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566 · cited 1×
“Mass-spectrometry (MS)-based approaches have demonstrated the ability to quantify abundances of thousands of mammalian proteins in parallel [57-60].”
BackgroundMass-spectrometric exploration of proteome structure and function
Aebersold, R., & Mann, M. (2016) · Nature · doi:10.1038/nature19949 · Cited by 2,334 · cited 7×
“Mann M, Kulak NA, Nagaraj N, Cox J.”
MethodInfluentialA Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 3×
“Although codons 12, 13, and 61 are in regions that are identical for all RAS isoforms, the distribution of oncogenic mutations differs between these isoforms [21].”
BackgroundInfluentialDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · cited 1×
“Recently, methods to inhibit RAS, once thought of as an “undruggable” target, are showing promise [105].”
BackgroundGEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903 · cited 1×
“, RASA1, NF1, SYNGAP1, RASAL1, RASA3-4) prompt the reverse transition by accelerating GTP hydrolysis [8-13].”
BackgroundKulak, N. A., Pichler, G., Paron, I., Nagaraj, N., & Mann, M. (2014) · Nature Methods · doi:10.1038/nmeth.2834 · Cited by 1,719 · cited 1×
“Mass-spectrometry (MS)-based approaches have demonstrated the ability to quantify abundances of thousands of mammalian proteins in parallel [57-60].”
BackgroundCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
A Cytoplasmic Protein Stimulates Normal N- ras p21 GTPase, But Does Not Affect Oncogenic Mutants
Trahey, M., & McCormick, F. (1987) · Science · doi:10.1126/science.2821624 · Cited by 1,211 · cited 1×
“As intracellular GTP/GDP ratios are estimated to be greater than 10 under nutrient replete conditions [6,7], a free RAS G domain is more likely to bind GTP than GDP.”
BackgroundDeep proteome and transcriptome mapping of a human cancer cell line
Nagaraj, N., Wisniewski, J. R., Geiger, T., Cox, J., Kircher, M., Kelso, J., Pääbo, S., & Mann, M. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.81 · Cited by 979 · cited 1×
“Mass-spectrometry (MS)-based approaches have demonstrated the ability to quantify abundances of thousands of mammalian proteins in parallel [57-60].”
BackgroundGeiger, T., Wehner, A., Schaab, C., Cox, J., & Mann, M. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.014050 · Cited by 797 · cited 1×
“Mass-spectrometry (MS)-based approaches have demonstrated the ability to quantify abundances of thousands of mammalian proteins in parallel [57-60].”
Background
Research works printed but not linked: 143
- Barbacid, 1987, Ras genes, Annu. Rev. Biochem., 56, 779, 10.1146/annurev.bi.56.070187.004023 · DOI · Paper page
- Colicelli, 2004, Human RAS superfamily proteins and related GTPases, Sci. STKE, 250, RE13
- Novotny, 2017, Farnesyltransferase-mediated delivery of a covalent inhibitor overcomes alternative prenylation to mislocalize K‐Ras, ACS Chem. Biol., 12, 1956, 10.1021/acschembio.7b00374 · DOI · Paper page
- Ho, 2017, An open-label, phase II study of tipifarnib for the treatment of HRAS mutant solid tumors, including squamous cell carcinomas of the head and neck, J. Clin. Oncol., 35, 10.1200/JCO.2017.35.15_suppl.TPS2618 · doi:10.1200/jco.2017.35.15_suppl.tps2618
- Pilz, 1997, A decrease in the intracellular guanosine concentration is necessary for granulocytic differentiation of HL-60Cells, but growth cessation and differentiation are not associated with a change in the activation state of ras, the transforming principle of, Cell Growth Differ., 8, 53
- Allin, 2001, Monitoring the GAP catalyzed H-Ras GTPase reaction at atomic resolution in real time, Proc. Natl. Acad. Sci., 98, 7754, 10.1073/pnas.131549798 · DOI
- Allin, 2001, Ras catalyzes GTP hydrolysis by shifting negative charges from γ-to phosphate as revealed by time-resolved FTIR difference spectroscopy, Biochemistry, 40, 3037, 10.1021/bi0017024 · DOI
- Ahmadian, 1997, Confirmation of the arginine-finger hypothesis for the GAP-stimulated GTP-hydrolysis reaction of Ras, Nat. Struct. Mol. Biol., 4, 686, 10.1038/nsb0997-686 · DOI · Paper page
- Vigil, 2010, Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?, Nat. Rev. Cancer, 10, 842, 10.1038/nrc2960 · DOI · Paper page
- Denhardt, 1996, Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling, Biochem. J., 318, 729, 10.1042/bj3180729 · DOI · Paper page
- McLaughlin, 2013, The RasGAP gene, RASAL2, is a tumor and metastasis suppressor, Cancer Cell, 24, 365, 10.1016/j.ccr.2013.08.004 · DOI · Paper page
- Sung, 2016, Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation, Oncotarget, 7, 23885, 10.18632/oncotarget.8127 · DOI
- Markevich, 2004, Signal processing at the Ras circuit: what shapes Ras activation patterns?, Syst. Biol. (Stevenage), 1, 104, 10.1049/sb:20045003 · DOI · Paper page
- Neel, 2011, The RalGEF-Ral effector signaling network: the road less traveled for anti-Ras drug discovery, Genes Cancer, 2, 275, 10.1177/1947601911407329 · DOI · Paper page
- Shankar, 2016, KRAS engages AGO2 to enhance cellular transformation, Cell Rep., 14, 1448, 10.1016/j.celrep.2016.01.034 · DOI · Paper page
- Joneson, 1997, Ras effectors and their role in mitogenesis and oncogenesis, J. Mod. Med., 75, 587
- Castellano, 2011, Functional specificity of ras isoforms: so similar but so different, Genes Cancer, 2, 216, 10.1177/1947601911408081 · DOI · Paper page
- Vu, 2016, Targeting mutant NRAS signaling pathways in melanoma, Pharmacol. Res., 107, 111, 10.1016/j.phrs.2016.03.007 · DOI
- T. Cancer Genome Atlas Research Network, 2013, The cancer genome atlas pan-cancer analysis project, Nat. Genet., 45, 1113, 10.1038/ng.2764 · DOI · Paper page
- Stites, 2012, Mechanistic modeling to investigate signaling by oncogenic Ras mutants, Wiley Interdiscip. Rev. Syst. Biol. Med., 4, 117, 10.1002/wsbm.156 · DOI
- Brightman, 2000, Differential feedback regulation of the MAPK cascade underlies the quantitative differences in EGF and NGF signalling in PC12 cells, FEBS Lett., 482, 169, 10.1016/S0014-5793(00)02037-8 · DOI · Paper page
- Schoeberl, 2002, Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors, Nat. Biotechnol., 20, 370, 10.1038/nbt0402-370 · DOI · Paper page
- Kholodenko, 1999, Quantification of short term signaling by the epidermal growth factor receptor, J. Biol. Chem., 274, 30169, 10.1074/jbc.274.42.30169 · DOI · Paper page
- Orton, 2005, Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway, Biochem. J., 392, 249, 10.1042/BJ20050908 · DOI · Paper page
- Stites, 2007, Network analysis of oncogenic ras activation in cancer, Science, 318, 463, 10.1126/science.1144642 · DOI · Paper page
- Orton, 2009, Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway, BMC Syst. Biol., 3, 100, 10.1186/1752-0509-3-100 · DOI
- Stites, 2015, Cooperation between noncanonical ras network mutations, Cell Rep., 10, 307, 10.1016/j.celrep.2014.12.035 · DOI · Paper page
- Kholodenko, 2010, Signalling ballet in space and time, Nat. Rev. Mol. Cell Biol., 11, 414, 10.1038/nrm2901 · DOI · Paper page
- Buhrman, 2010, Allosteric modulation of Ras positions Q61 for a direct role in catalysis, Proc. Natl. Acad. Sci., 107, 4931, 10.1073/pnas.0912226107 · DOI · Paper page
- Ihle, 2012, Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome, J. Natl. Cancer Inst., 104, 228, 10.1093/jnci/djr523 · DOI · Paper page
- Margarit, 2003, Structural evidence for feedback activation by Ras·GTP of the Ras-specific nucleotide exchange factor SOS, Cell, 112, 685, 10.1016/S0092-8674(03)00149-1 · DOI · Paper page
- Gremer, 2010, Duplication of Glu 37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation, Hum. Mol. Genet., 19, 790, 10.1093/hmg/ddp548 · DOI
- Cirstea, 2013, Diverging gain-of-function mechanisms of two novel KRAS mutations associated with Noonan and cardio-facio-cutaneous syndromes, Hum. Mol. Genet., 22, 262, 10.1093/hmg/dds426 · DOI · Paper page
- Denayer, 2008, Mutation analysis in costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation, Hum. Mutat., 29, 232, 10.1002/humu.20616 · DOI
- Kenney, 2017, A computational panel of pathological RAS mutants with implications for personalized medicine and genetic medicine, bioRxiv
- Stites, 2014, Differences in sensitivity to EGFR inhibitors could be explained by described biochemical differences between oncogenic Ras mutants, bioRxiv
- Kiel, 2014, Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations, Mol. Syst. Biol., 10, 727, 10.1002/msb.20145092 · DOI · Paper page
- Baldwin, 2009, NMR spectroscopy brings invisible protein states into focus, Nat. Chem. Biol., 5, 808, 10.1038/nchembio.238 · DOI · Paper page
- Mittermaier, 2009, Observing biological dynamics at atomic resolution using NMR, Trends Biochem. Sci., 601, 10.1016/j.tibs.2009.07.004 · DOI · Paper page
- Theillet, 2012, Cell signaling, post-translational protein modifications and NMR spectroscopy, J. Biomol. NMR, 54, 217, 10.1007/s10858-012-9674-x · DOI · Paper page
- Hause, 2012, Comprehensive binary interaction mapping of SH2 domains via fluorescence polarization reveals novel functional diversification of ErbB receptors, PLoS One, 7, e44471, 10.1371/journal.pone.0044471 · DOI
- Kaushansky, 2010, Quantifying protein-protein interactions in high throughput using protein domain microarrays, Nat. Protoc., 5, 773, 10.1038/nprot.2010.36 · DOI · Paper page
- Vincentelli, 2015, Quantifying domain-ligand affinities and specificities by high-throughput holdup assay, Nat. Methods, 12, 787, 10.1038/nmeth.3438 · DOI · Paper page
- Kowalsky, 2016, Determination of binding affinity upon mutation for type I dockerin-cohesion complexes from Clostridium thermocellum and Clostridium cellulolyticum using deep sequencing, Proteins Struct. Funct. Bioinformatics, 84, 1914, 10.1002/prot.25175 · DOI
- Stites, 2015, Use of mechanistic models to integrate and analyze multiple proteomic datasets, Biophys. J., 108, 1819, 10.1016/j.bpj.2015.02.030 · DOI
- Kiel, 2014, Quantification of ErbB network proteins in three cell types using complementary approaches identifies cell-general and cell-type-specific signaling proteins, J. Proteome Res., 13, 300, 10.1021/pr400878x · DOI
- Shi, 2012, Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum, Proc. Natl. Acad. Sci., 109, 15395, 10.1073/pnas.1204366109 · DOI · Paper page
- Shi, 2016, Conservation of protein abundance patterns reveals the regulatory architecture of the EGFR-MAPK pathway, Sci. Signal., 9, 10.1126/scisignal.aaf0891 · DOI · Paper page
- Sudhir, 2011, Phosphoproteomics identifies oncogenic Ras signaling targets and their involvement in lung adenocarcinomas, PLoS One, 6, 10.1371/journal.pone.0020199 · DOI
- Gnad, 2013, Systems-wide analysis of K-Ras, Cdc42, and PAK4 signaling by quantitative phosphoproteomics, Mol. Cell. Proteomics, 12, 2070, 10.1074/mcp.M112.027052 · DOI
- Moritz, 2010, Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases, Sci. Signal., 3, 10.1126/scisignal.2000998 · DOI · Paper page
- Shalem, 2014, Genome-scale CRISPR-Cas9 knockout screening in human cells, Science, 343, 84, 10.1126/science.1247005 · DOI · Paper page
- Wang, 2014, Genetic screens in human cells using the CRISPR-Cas9 system, Science, 343, 80, 10.1126/science.1246981 · DOI · Paper page
- Cong, 2013, Multiplex genome engineering using CRISPR/Cas systems, Science, 339, 819, 10.1126/science.1231143 · DOI · Paper page
- Mali, 2013, RNA-guided human genome engineering via Cas9, Science, 339, 823, 10.1126/science.1232033 · DOI · Paper page
- Konermann, 2015, Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex, Nature, 517, 583, 10.1038/nature14136 · DOI · Paper page
- Young, 2013, SHOC2, and SCRIB complex coordinates ERK pathway activation with polarity and tumorigenic growth, Mol. Cell, 52, 679, 10.1016/j.molcel.2013.10.004 · DOI
- Harvey, 2008, The spread of ras activity triggered by activation of a single dendritic spine, Science, 321, 136, 10.1126/science.1159675 · DOI · Paper page
- Kholodenko, 2009, Spatially distributed cell signalling, FEBS Lett., 583, 4006, 10.1016/j.febslet.2009.09.045 · DOI
- Tsyganov, 2012, The topology design principles that determine the spatiotemporal dynamics of G-protein cascades, Mol. Biosyst., 8, 730, 10.1039/c2mb05375f · DOI
- Muñoz-García, 2010, Signalling over a distance: gradient patterns and phosphorylation waves within single cells, Biochem. Soc. Trans., 38, 10.1042/BST0381235 · DOI
- Verissimo, 2016, Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening, Elife, e18489, 10.7554/eLife.18489 · DOI · Paper page
- Harvey, 2008, A genetically encoded fluorescent sensor of ERK activity, Proc. Natl. Acad. Sci., 105, 19264, 10.1073/pnas.0804598105 · DOI · Paper page
- Albeck, 2013, Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals, Mol. Cell, 49, 249, 10.1016/j.molcel.2012.11.002 · DOI · Paper page
- Ryu, 2015, Frequency modulation of ERK activation dynamics rewires cell fate, Mol. Syst. Biol., 11, 10.15252/msb.20156458 · DOI · Paper page
- Vandame, 2014, Optimization of ERK activity biosensors for both ratiometric and lifetime FRET measurements, Sensors, 14, 1140, 10.3390/s140101140 · doi:10.3390/s140101140
- Regot, 2014, High-sensitivity measurements of multiple kinase activities in live single cells, Cell, 157, 1724, 10.1016/j.cell.2014.04.039 · DOI · Paper page
- Toettcher, 2013, Using optogenetics to interrogate the dynamic control of signal transmission by the Ras/Erk module, Cell, 155, 1422, 10.1016/j.cell.2013.11.004 · DOI · Paper page
- Levskaya, 2009, Spatiotemporal control of cell signalling using a light- switchable protein interaction, Nature, 461, 997, 10.1038/nature08446 · DOI · Paper page
- Druker, 1996, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells, Nat. Med., 2, 561, 10.1038/nm0596-561 · DOI · Paper page
- Deininger, 2003, Specific targeted therapy of chronic myelogenous leukemia with imatinib, Pharmacol. Rev., 55, 401, 10.1124/pr.55.3.4 · DOI · Paper page
- Flaherty, 2010, Inhibition of mutated, activated BRAF in metastatic melanoma, N. Engl. J. Med., 363, 809, 10.1056/NEJMoa1002011 · DOI · Paper page
- Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 · DOI · Paper page
- Swaika, 2014, Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma, Drug Des Dev. Ther., 4, 775
- Cohen, 2003, FDA drug approval summary gefitinib (ZD1839) (Iressa) tablets, Oncologist, 8, 303, 10.1634/theoncologist.8-4-303 · DOI · Paper page
- Khozin, 2014, U. S. Food and drug administration approval summary: erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations, Oncologist, 21, 774, 10.1634/theoncologist.2014-0089 · DOI · Paper page
- Keating, 2014, Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer, Drugs, 74, 207, 10.1007/s40265-013-0170-8 · DOI
- Wu, 2015, FDA-approved small-molecule kinase inhibitors, Trends Pharmacol. Sci., 36, 422, 10.1016/j.tips.2015.04.005 · DOI · Paper page
- Stuhlmiller, 2015, Inhibition of lapatinib-Induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains, Cell Rep., 11, 390, 10.1016/j.celrep.2015.03.037 · DOI · Paper page
- Liu, 2016, Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells, Oncogene, 7, 9135
- Robert, 2015, Improved overall survival in melanoma with combined dabrafenib and trametinib, N. Engl. J. Med., 372, 10.1056/NEJMoa1412690 · DOI · Paper page
- Smith, 2007, 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial, Lancet, 369, 29, 10.1016/S0140-6736(07)60028-2 · DOI · Paper page
- Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 376, 687, 10.1016/S0140-6736(10)61121-X · DOI · Paper page
- Ostrem, 2013, K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions, Nature, 503, 548, 10.1038/nature12796 · DOI · Paper page
- Papke, 2016, Identification of pyrazolopyridazinones as PDEδ inhibitors, Nat. Commun., 7, 11360, 10.1038/ncomms11360 · DOI · Paper page
- Dekker, 2010, Small-molecule inhibition of APT1 affects Ras localization and signaling, Nat. Chem. Biol., 6, 449, 10.1038/nchembio.362 · DOI · Paper page
- Najumudeen, 2016, Cancer stem cell drugs target K-ras signaling in a stemness context, Oncogene, 35, 5248, 10.1038/onc.2016.59 · DOI
- Holohan, 2013, Cancer drug resistance: an evolving paradigm, Nat. Rev. Cancer, 13, 714, 10.1038/nrc3599 · DOI · Paper page
- Pao, 2005, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Med., 2, e73, 10.1371/journal.pmed.0020073 · DOI · Paper page
- Aplin, 2011, Mechanisms of resistance to RAF inhibitors in melanoma, J. Invest. Dermatol., 131, 1817, 10.1038/jid.2011.147 · DOI
- Montagut, 2008, Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma, Cancer Res., 68, 4853, 10.1158/0008-5472.CAN-07-6787 · DOI · Paper page
- Iadevaia, 2010, Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis, Cancer Res., 70, 6704, 10.1158/0008-5472.CAN-10-0460 · DOI · Paper page
- Waters, 1996, Insulin and epidermal growth factor receptors regulate distinct pools of Grb2-SOS in the control of ras activation, J. Biol. Chem., 271, 18224, 10.1074/jbc.271.30.18224 · DOI
- Hennig, 2016, Feedback activation of neurofibromin terminates growth factor-induced Ras activation, Cell Commun. Signal., 14, 10.1186/s12964-016-0128-z · DOI · Paper page
- Catalanotti, 2009, A Mek1–Mek2 heterodimer determines the strength and duration of the Erk signal, Nat. Struct. Mol. Biol., 16, 294, 10.1038/nsmb.1564 · DOI · Paper page
- Brunet, 1994, Growth factor-stimulated MAP kinase induces rapid retrophosphorylation and inhibition of MAP kinase kinase (MEK1), FEBS Lett., 346, 299, 10.1016/0014-5793(94)00475-7 · DOI
- Corbalan-Garcia, 1996, Identification of the mitogen-activated protein kinase phosphorylation sites on human sos1 that regulate interaction with Grb2, Mol. Cell. Biol., 16, 5674, 10.1128/MCB.16.10.5674 · DOI · Paper page
- Chen, 1996, SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways, J. Biol. Chem., 271, 6328, 10.1074/jbc.271.11.6328 · DOI · Paper page
- Waters, 1995, Desensitization of ras activation by a feedback disassociation of the SOS-Grb2 complex, J. Biol. Chem., 270, 20883, 10.1074/jbc.270.36.20883 · DOI · Paper page
- Dougherty, 2005, Regulation of Raf-1 by direct feedback phosphorylation, Mol. Cell, 17, 215, 10.1016/j.molcel.2004.11.055 · DOI · Paper page
- Ritt, 2010, Impact of feedback phosphorylation and raf heterodimerization on normal and mutant B-Raf signaling, Mol. Cell Biol., 30, 806, 10.1128/MCB.00569-09 · DOI · Paper page
- Gross, 2001, Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation, J. Biol. Chem., 276, 46460, 10.1074/jbc.M108234200 · DOI · Paper page
- Lim, 2000, Sprouty proteins are targeted to membrane ruffles upon growth factor receptor tyrosine kinase activation, J. Biol. Chem., 275, 32837, 10.1074/jbc.M002156200 · DOI
- Masoumi-Moghaddam, 2014, The developing story of Sprouty and cancer, Cancer Metastasis Rev., 33, 695, 10.1007/s10555-014-9497-1 · DOI · Paper page
- Mason, 2006, Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling, Trends Cell Biol., 16, 45, 10.1016/j.tcb.2005.11.004 · DOI · Paper page
- Rubin, 2005, Phosphorylation of carboxyl-terminal tyrosines modulates the specificity of sprouty-2 inhibition of different signaling pathways, J. Biol. Chem., 280, 9735, 10.1074/jbc.M408308200 · DOI
- Tsavachidou, 2004, SPRY2 is an inhibitor of the Ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant, Cancer Res., 64, 5556, 10.1158/0008-5472.CAN-04-1669 · DOI · Paper page
- Tefft, 2002, mSprouty2 inhibits FGF10-activated MAP kinase by differentially binding to upstream target proteins, Am. J. Physiol. Lung Cell Mol. Physiol., 283, L700, 10.1152/ajplung.00372.2001 · DOI · Paper page
- Boykevisch, 2006, Regulation of Ras signaling dynamics by sos-mediated positive feedback, Curr. Biol., 16, 2173, 10.1016/j.cub.2006.09.033 · DOI
- Freedman, 2006, A Ras-induced conformational switch in the Ras activator Son of sevenless, Proc. Natl. Acad. Sci., 103, 16692, 10.1073/pnas.0608127103 · DOI · Paper page
- Sondermann, 2004, Structural analysis of autoinhibition in the Ras activator son of sevenless, Cell, 119, 393, 10.1016/j.cell.2004.10.005 · DOI · Paper page
- Lun, 2017, Influence of node abundance on signaling network state and dynamics analyzed by mass cytometry, Nat. Biotechnol., 35, 164, 10.1038/nbt.3770 · DOI
- Birtwistle, 2012, Emergence of bimodal cell population responses from the interplay between analog single-cell signaling and protein expression noise, BMC Syst. Biol., 6, 109, 10.1186/1752-0509-6-109 · DOI · Paper page
- Dobrzynski, 2014, Nonlinear signalling networks and cell- to-cell variability transform external signals into broadly distributed or bimodal responses, J. R. Soc. Interface, 11, 20140383, 10.1098/rsif.2014.0383 · DOI
- Dobrzynski, 2012, Bimodal protein distributions in heterogeneous oscillating systems, Lect. Notes Comput. Sci., 17, 10.1007/978-3-642-33636-2_3 · DOI
- Shin, 2008, Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway, J. Cell Sci., 122, 425, 10.1242/jcs.036319 · DOI · Paper page
- Bluthgen, 2006, Effects of sequestration on signal transduction cascades, FEBS J., 273, 895, 10.1111/j.1742-4658.2006.05105.x · DOI
- Markevich, 2004, Signaling switches and bistability arising from multisite phosphorylation in protein kinase cascades, J. Cell Biol., 164, 353, 10.1083/jcb.200308060 · DOI · Paper page
- Muller, 2001, C-TAK1 regulates ras signaling by phosphorylating the MAPK scaffold, KSR1, Mol. Cell, 8, 983, 10.1016/S1097-2765(01)00383-5 · DOI · Paper page
- Lemmon, 2010, Cell signaling by receptor tyrosine kinases, Cell, 1117, 10.1016/j.cell.2010.06.011 · DOI · Paper page
- Markevich, 2006, Long-range signaling by phosphoprotein waves arising from bistability in protein kinase cascades, Mol. Syst. Biol., 2, 61, 10.1038/msb4100108 · DOI
- Prior, 2012, Ras trafficking, localization and compartmentalized signalling, Semin. Cell Dev. Biol., 23, 145, 10.1016/j.semcdb.2011.09.002 · DOI · Paper page
- Fivaz, 2005, Reversible intracellular translocation of KRas but not HRas in hippocampal neurons regulated by Ca 2, J. Cell Biol., 170, 429, 10.1083/jcb.200409157 · DOI · Paper page
- Kranenburg, 2001, Regulating c-Ras function: cholesterol depletion affects caveolin association, GTP loading, and signaling, Curr. Biol., 11, 1880, 10.1016/S0960-9822(01)00582-6 · DOI
- Matallanas, 2006, Distinct utilization of effectors and biological outcomes resulting from site-specific ras activation: ras functions in lipid rafts and golgi complex are dispensable for proliferation and transformation, Mol. Cell Biol., 26, 100, 10.1128/MCB.26.1.100-116.2006 · DOI · Paper page
- Nakhaeizadeh, 2016, The RAS-effector interface: isoform-specific differences in the effector binding regions, PLoS One, 11, e0167145, 10.1371/journal.pone.0167145 · DOI · Paper page
- Fey, 2015, Signaling pathway models as biomarkers: patient-specific simulations of JNK activity predict the survival of neuroblastoma patients, Sci. Signal., 8, ra130, 10.1126/scisignal.aab0990 · DOI · Paper page
- Chmielecki, 2011, Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling, Sci. Transl. Med., 3, 10.1126/scitranslmed.3002356 · DOI · Paper page
- Gallaher, 2018, Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies, Cancer Res., 10.1158/0008-5472.CAN-17-2649 · DOI · Paper page
- Enriquez-Navas, 2016, Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer, Sci. Transl. Med., 8, 10.1126/scitranslmed.aad7842 · DOI · Paper page
- Shain, 2015, A multidisciplinary model predicts clinical response in relapsed multiple myeloma, Blood, 126, 501, 10.1182/blood.V126.23.501.501 · doi:10.1182/blood.v126.23.501.501
- Altrock, 2016, Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease, Am. J. Hematol., 91, 931, 10.1002/ajh.24449 · DOI · Paper page
- Serre, 2016, Mathematical modeling of cancer immunotherapy and its synergy with radiotherapy, Cancer Res., 76, 4931, 10.1158/0008-5472.CAN-15-3567 · DOI · Paper page
- Kim, 2016, Phase i trials in melanoma: a framework to translate preclinical findings to the clinic, Eur. J. Cancer., 67, 213, 10.1016/j.ejca.2016.07.024 · DOI
- Chakrabarti, 2017, Pharmacokinetics and drug interactions determine optimum combination strategies in computational models of cancer evolution, Cancer Res., 77, 3908, 10.1158/0008-5472.CAN-16-2871 · DOI
- Kolch, 2015, The dynamic control of signal transduction networks in cancer cells, Nat. Rev. Cancer, 15, 515, 10.1038/nrc3983 · DOI · Paper page
- Lenzen, 1998, Kinetic analysis by fluorescence of the interaction between ras and the catalytic domain of the guanine nucleotide exchange factor Cdc25 mm, Biochemistry, 2960, 7420, 10.1021/bi972621j · DOI · Paper page
- Eccleston, 1991, Fluorescence approaches to the study of the p21ras GTPase mechanism, Biochem. Soc. Trans., 19, 432, 10.1042/bst0190432 · DOI
- Wey, 2013, Kinetic mechanisms of mutation-dependent harvey Ras activation and their relevance for the development of costello syndrome, Biochemistry, 52, 8465, 10.1021/bi400679q · DOI · Paper page
- Donovan, 1602, GTPase activating proteins: critical regulators of intracellular signaling, Biochim. Biophys. Acta, 2002, 23
- Bollag, 1996, Biochemical characterization of a novel KRAS insertion mutation from a human leukemia, J. Biol. Chem., 271, 32491, 10.1074/jbc.271.51.32491 · DOI · Paper page
- John, 1988, Biochemical properties of Ha-ras encoded p21 mutants and mechanism of the autophosphorylation reaction, J. Biol. Chem., 263, 11792, 10.1016/S0021-9258(18)37854-2 · DOI · Paper page
- Smith, 2017, Evolution of AF6-RAS association and its implications in mixed-lineage leukemia, Nat. Commun., 8, 1099, 10.1038/s41467-017-01326-5 · DOI · Paper page
Cited by
Optogenetic actuator – ERK biosensor circuits identify MAPK network nodes that shape ERK dynamics
Dessauges, C., Mikelson, J., Dobrzyński, M., Jacques, M., Frismantiene, A., Gagliardi, P. A., Khammash, M., & Pertz, O. (2022) · Molecular Systems Biology · doi:10.15252/msb.202110670 · Cited by 48
Zhang, Y., Li, C., Xia, C., Wah To, K. K., Guo, Z., Ren, C., Wen, L., Wang, F., Fu, L., & Liao, N. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00955-8 · Cited by 33
Optogenetic actuator/ERK biosensor circuits identify MAPK network nodes that shape ERK dynamics
Dessauges, C., Mikelson, J., Dobrzyński, M., Jacques, M.-A., Frismantiene, A., Gagliardi, P. A., Khammash, M., & Pertz, O. (2021) · doi:10.1101/2021.07.27.453955 · Cited by 9
Mesoscale simulations of membrane-tethered reactions to parameterize cell-scale models of signaling
Peterson, K. J., Slepchenko, B. M., & Loew, L. M. (2026) · Biophysical Journal · doi:10.1016/j.bpj.2026.04.015 · Cited by 1
Metadata
- Authors
- Erickson, K. E., Rukhlenko, O. S., Posner, R. G., Hlavacek, W. S., & Kholodenko, B. N.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 54
- Pages
- 162-173
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2790200234
- Cited by
- 19
- References
- 38
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 398 d)
- Funders
- Joint Design of Advanced Computing Solutions for Cancer
- National Institutes of Health (GM111510)
- NIH/NCI (CA197398)
- European Union grants SmartNanoTox (686098)
- NanoCommons (731032)
- MSCA-IF-2016 SAMNets (750688)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.